Skip to main content

Find a clinical trial

Find a clinical trial

Trial status
Trial Phase
Trial type
23 clinical trials grid list download
  • Title Organ Phase Statut Major inclusion criteria Contact
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1 Ahmad Hussein Awada
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1 Philippe Aftimos
  • CA045-001 A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma Skin phase 3 Closed Stage III or IV, unresecable Joseph Kerger
  • CA209-8RX A national, prospective, Therapeutic Non-Interventional Clinical Trial (TNICT) in patients receiving adjuvant nivolumab therapy for resected melanoma Skin phase 4 Open Complete resection Joseph Kerger
  • CA209358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors Multiple phase 1/2 Closed ECOG 0 or 1 Ahmad Hussein Awada
  • COBRIM GO28141 A phase III, double-blind, placebo-controlled study of Vemurafenib versus Vemurafenib plus GDC-0973 in previously untreated BRAFV600-mutation positive patients with unresectable locally Advanced or metastatic melanoma Skin phase 3 Closed BRAF V600 mutation Joseph Kerger
  • EMR 200066-007 A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with NRas mutated locally advanced or metastatic malignant cutaneous melanoma Skin phase 2 Closed N-Ras mutated Joseph Kerger
  • EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Lung Closed any line / Lung metastasis Konstantinos Stathopoulos
  • EVICTION A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer Multiple phase 1 Open Relasped/refractory patient Christiane Jungels
  • GO29674 A Phase Ib, Open-Label, Dose-escalation Study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors Multiple phase 1 Closed any line Ahmad Hussein Awada
  • I3Y-MC-JPBO A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer, non-small cell lung cancer, or melanoma Multiple phase 2 Closed Brain metastasis Ahmad Hussein Awada
  • I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Multiple phase 1 Closed RECIST 1.1, after standard trerapy Ahmad Hussein Awada
  • IJB_2672 A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older Multiple phase 3 Open vaccine, diarrhea, clostridium Mickael Aoun
  • IJB_2728 Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention Solid tumors Open Metastatic, any tumors